

GPIAG

Patient Group Direction

PGD Number 1
Issue: 01

Date: October 2008



The supply/administration of salbutamol for reversibility testing in primary care by a designated healthcare professional

For PCT use only:

PCT Implementation date	
Review date	

Approval for use and Implementation

	Authorising Professional	Name	Signature	Date
This PGD has been approved and authorised for use:	PCT Clinical Governance Chair or other authorising person			
	PCT Prescribing Manager or other prescribing advisor authorised to sign			

Approval by the appropriate manager for the healthcare professional listed below to administer salbutamol MDI where reversibility testing is indicated :

	Authorising Professional	Name	Signature	Date
For PCT employed staff only:	Manager of healthcare professional			
For Primary Care Practice staff only:	GP/Authorising professional			

Agreement by healthcare professional to administer the medicine in accordance with the PGD

I hereby confirm that I have read and agree to administer the medicine in accordance with this directive

Health Professional Name	Position	Signature	Date

Review

Plan a review to enable completion prior to the date of the next review listed above. Retain a copy of each version of the Patient Group Direction for ten years.

A copy of this PGD should be given to the PCT, the healthcare professional(s) listed above, their manager(s) and the original is to be retained by the Prescribing Advisor/Manager

This patient group direction (PGD) has been developed specifically to be utilised by primary care nurses delivering respiratory care. It has been produced as a general guide only. It must be stressed that the use of all, or part, of this PGD must be sanctioned and approved by the appropriate authorised individual from the practice and/or primary care organisation in which it is to be used. The GPIAG is neither responsible or liable, directly or indirectly for any form of damage or injury caused as a result of information provided in this document.

Date of Preparation: October 2008

Author: Stephanie Reilly, Lead COPD Nurse Specialist, Derby Review and Input: GPIAG Practice Nurse Committee Editor: Dr Mark Levy, GPIAG
Websites: <http://www.gpiag.org>, <http://www.thepcrj.org> ©GPIAG. See website for terms and conditions <http://www.gpiag.org/about/disclaimer.php>.

The GPIAG is a registered charity (Charity Number: 1098117) and a company limited by guarantee (Company number 4298947).

Registered Offices: 2 Wellington Place, Leeds, LS1 4AP

Address for Correspondence: GPIAG, Smithy House, Waterbeck, Lockerbie, DG11 3EY, UK +

Tel: 44 (0)1461 600639 Facsimile: +44 (0)1361 331811 Email: fo@gpiag.org

The supply/administration of salbutamol for reversibility testing in primary care by a designated healthcare professional

Clinical Condition:

Define situation/condition	Registered healthcare professionals in primary care may administer salbutamol MDI in the manner outlined below without medical prescription
Criteria for inclusion	<ol style="list-style-type: none"> 1. For the purpose of assessing bronchodilator reversibility 2. For use in spirometry for reversibility testing in accordance with reversibility testing protocol
Criteria for exclusion	Patients who are excluded from lung function testing as per spirometry exclusion criteria
Action if excluded	Refer to GP and rearrange appointment
Action if patient declines	Refer to GP

Characteristics of staff:

Qualifications required	Registered healthcare professional
Additional requirements	<ol style="list-style-type: none"> 1. Knowledge of the local COPD guidelines and/or National Institute for health and Clinical Excellence (NICE) Management of COPD Guideline 2004 (http://www.nice.org.uk/guidance/CG12) 2. Knowledge of British Thoracic Society (BTS)/Scottish Intercollegiate Guideline Network (SIGN) guideline for the management of asthma (2008) http://www.sign.ac.uk/guidelines/fulltext/101/index.html 3. Must be trained and competent in the use of spirometry and be informed of current best practice http://www.gpiag.org/resources/protocol01_spirometry_final.pdf
Continued training requirements	Evidence of training related to the use of spirometry and the use of this drug

Description of Treatment

Name of medicine	Salbutamol 100 micrograms (mcg)
POM/P/GSL	POM
Dose/s	Aerosol inhalation - adults 400mcg
Route/method	Inhalation from inhaler via a large volume spacer device
Frequency	Once only
Total dose/number	Once only
Information on follow-up treatment	Advise patient on future therapy including referral to doctor or nurse-led respiratory clinic as appropriate
Written/verbal advice for patient/carer before/after treatment	As above
Specify method of recording supply/administration sufficient to include audit	The healthcare professional must record the administration of salbutamol in the clinical record. The name of the drug, dose given and batch number of the drug used must also be recorded

Procedure for reporting Adverse Drug Reactions (ADRs):

All ADRs must be reported in the clinical record, the doctor must be informed and the incident reported on a yellow card to the Committee on the Safety of Medicines (CSM) - <http://www.bnf.org/bnf/bnf/current/yellow.htm>